CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Predictors of efficacy, mucosal healing and dose intensification at 12-months of adalimumab therapy in patients with Crohn's disease. National data from Hungary
DOI 10.1055/s-0031-1278470
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL Kiss, P Miheller, T Molnár, L Lakatos, Á Vincze, K Palatka, B Gosztonyi, Á Salamon, G Horváth, K Farkas, T Szamosi, J Banai, Z Tulassay, M Papp, P Lakatos
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background/Aims: Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor with proven efficacy in the treatment of Crohn's disease (CD) in clinical trials. In the present study our aim was to investigate the accuracy of clinical and laboratory markers for the prediction of medium term efficacy and mucosal healing during adalimumab therapy in patients with CD in specialized centers approved for…
Zitieren
Zitierempfehlung
L Kiss, P Miheller, T Molnár, L Lakatos, Á Vincze, K Palatka, B Gosztonyi, Á Salamon, G Horváth, K Farkas, T Szamosi, J Banai, Z Tulassay, M Papp, P Lakatos (2011) Predictors of efficacy, mucosal healing and dose intensification at 12-months of adalimumab therapy in patients with Crohn's disease. National data from Hungary. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0031-1278470
Mit CareLit weiterarbeiten